Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2020 / Small Molecules / Niklas Sandler

Niklas Sandler

Chief Technology Officer at Nanoform

  • Profile

Meet Niklas Sandler

Niklas Sandler has extensive experience in both industry and academia, particularly within the fields of pharmaceutical product development and material science. Alongside his role as chief technology officer at Nanoform, he is also a professor at Åbo Akademi University with over 100 published  papers in several pharmaceutical journals.

When asked if small molecules were still a big for pharma, he responded:

“Small molecules are still a crucial part of development pipelines and cover many therapeutic areas. New technologies, including nanotechnology, will boost the potential of these molecules to create future therapies. Also, old treatments will benefit from technologies that improve drug performance and provide life cycle extension opportunities for existing drugs.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.